September is the official world Alzheimer’s month, raising awareness for this disease globally.
Approximately 50 million people suffer from dementia worldwide, and in Sweden, it afflicts approximately 160,000 people. Of those, around 60% are diagnosed with Alzheimer’s disease. There is currently no cure or treatment that can stop the disease progression, but research is making great strides.
BioArctic’s drug candidate BAN2401 is now being studied in a global confirmatory Phase 3 study in patients with early Alzheimer’s disease. Read more about BAN2401.
BioArctic supports Alzheimerfonden’s important work in Sweden that contributes to continued research and increased knowledge in the community about Alzheimer’s disease.